LifeVantage Trial Results From New In Vitro Demonstrates All 14 Peptides Influences In Desired Direction

LifeVantage Corporation® (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced new in vitro study results for its proprietary P84 formula revealing strong biological activity in cellular pathways linked to gut regulation, repair, and restoration.

In the controlled, third-party study, targeted gene expression and protein concentration were measured using four gut cell types. Fourteen gut peptides and proteins known to regulate, repair, and restore the gut including CCK, NTS, EREG, GRP, OXM, CDH1, TFF3, Zonulin, CLDN1, OCLN, MUC2, GLP-2, VIP and SST were thoroughly examined.

All 14 peptides were influenced in the desired direction, with key results including: 

• GRP (gastrin-releasing peptide responsible for sending alerts to fire up digestion): +1,087% increase
• TFF3 (trefoil factor 3 which manages gut lining repair): +116% increase
• VIP (vasoactive intestinal peptide which helps to calm overactive areas of the gut): +100% increase
• OXM (oxyntomodulin which coordinates nutrient absorption): +77% increase
• CCK (cholecystokinin which ensures fats and proteins are properly processed): +69% increase